TCM
BHVN

Tekla Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Tekla Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-70,176
Closed -$10.6M – 179
2022
Q3 		$10.6M Hold
70,176
– – 0.43% 53
2022
Q2 		$10.2M Hold
70,176
– – 0.4% 60
2022
Q1 		$8.32M Hold
70,176
– – 0.29% 71
2021
Q4 		$9.67M Sell
70,176
-20,623
-23% -$2.62M 0.31% 71
2021
Q3 		$12.6M Buy
+90,799
New +$11.3M 0.41% 59
2020
Q4 		– Sell
-34,277
Closed -$2.23M – 216
2020
Q3 		$2.23M Hold
34,277
– – 0.08% 150
2020
Q2 		$2.51M Sell
34,277
-10,887
-24% -$579K 0.1% 150
2020
Q1 		$1.54M Buy
45,164
+16,039
+55% +$733K 0.07% 151
2019
Q4 		$1.59M Hold
29,125
– – 0.06% 159
2019
Q3 		$1.22M Buy
+29,125
New +$1.23M 0.05% 151
2018
Q2 		– Sell
-162,477
Closed -$4.18M – 198
2018
Q1 		$4.18M Buy
+162,477
New +$4.86M 0.16% 98

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Tekla Capital Management's BHVN Position: Q4 2022 in Review

Tekla Capital Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 70,176 shares — an estimated $10.6M sold.

Tekla Capital Management first reported a position in BHVN in Q1 2018 and held it in 11 quarters. The position peaked at $12.6M in Q3 2021. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Tekla Capital Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Tekla Capital Management sold 70,176 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $10.6M.
  • Tekla Capital Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2018 and held it in 11 quarters.
  • Tekla Capital Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $12.6M in Q3 2021.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Tekla Capital Management's 13F filing for Q4 2022, filed 10 Feb 2023.